AI Analysis
AI-generated analysis. Always verify with the original filing.
Protara Therapeutics announced a 68.0% six-month complete response rate in its Phase 2 ADVANCED-2 trial for TARA-002, triggering the exercise termination date fix for its April 2024 Common Warrants.
Key Takeaways
1The average six-month CR rate in 25 BCG-Unresponsive patients was 68.0%, consistent with the 68.2% rate announced on February 24, 2026.
2The reported 68.0% CR rate is meaningfully above the 41.9% threshold referenced in the disclosure.
3The Company determined it satisfied the condition for fixing the termination date for the April 2024 Common Warrants.
4April 2024 Common Warrants are exercisable at $5.25 per share and expire on June 29, 2026.